Baloxavir ≥ 98% CAS No：1985605-59-1
Baloxavir Powder,Baloxavir≥98%,1985605-59-1,C24H19F2N3O4S,Baroxavir
Content
Product Introduction
 | Product Name: Baloxavir Product purity: ≥ 98% CAS No：1985605-59-1 Molecular formula: C24H19F2N3O4S Molecular weight: 483.49 Detection method: HPLC Active ingredient: Baroxavir Product Description: White to light yellow oval shaped film coated sheet Product Usage: Patients with influenza A and B Product packaging: 20mg * 2 tablets/box Product storage: 2-8 ℃ Shelf life: 24 months Declaration of Use: This product is intended for industrial use or scientific research only. |
Products Description
Overview of Shaanxi Sunrise High-Purity Baloxavir Product
Shaanxi Sunrise focuses on providing high-purity baloxavir raw materials that meet strict pharmaceutical standards. Our products undergo precise synthesis processes and strict multi-level quality control systems (including advanced analytical techniques such as HPLC, GC, and MS), ensuring that the purity of the main component of baloxavir remains stable at ≥99%, and the content of key impurities is far lower than those stipulated in the pharmacopoeia and customer-specific requirements. The quality and effectiveness of the raw materials fully comply with standards. The baloxavir we provide meets the core requirements as a drug active ingredient (API), aiming to provide reliable and compliant high-quality raw materials for downstream formulation manufacturers, and help develop safe and effective anti-influenza drugs.
Choosing Shaanxi Sunrise, you will obtain a trustworthy partner in terms of quality and supply stability.
Products Function
Balosevir is the active metabolite of the anti influenza drug Mabosevir (trade name: Sifluza), and its core efficacy is:
1. Targeted inhibition of virus replication
By specifically inhibiting the "cap dependent endonuclease" (CEN) of influenza virus, blocking virus mRNA synthesis, the virus genome cannot replicate
The mechanism of action is different from neuraminidase inhibitors such as oseltamivir, which directly achieve "source blocking" in the early stage of virus replication
2. Quickly reduce viral load
Clinical studies have shown that a single dose significantly reduces viral load within 24 hours and shortens the duration of influenza symptoms by about 1 day
3. Broad spectrum antiviral activity
Effective against influenza A (including H1N1, H3N2, and avian influenza H5N1/H7N9) and influenza B viruses
Products Aplication
Balosevir, as an active pharmaceutical ingredient, is mainly used in the manufacture of anti influenza drug Mabosevir formulations (tablets/suspensions), and its clinical applications include:
Scope of indications | Advantages of drug administration |
Treatment of simple influenza A/B in adults and children aged ≥ 5 years (medication taken within 48 hours of symptom onset) Suitable for high-risk populations with influenza complications (such as chronic disease patients, elderly people)
| Single dose oral administration: only one dose is needed throughout the entire process, with high patient compliance Half life of up to 79-125 hours, with longer lasting efficacy than traditional drugs
|
product comparison
The characteristics of balosavir and other anti influenza drugs:
Characteristics | Balosavir | Oseltamivir |
Mechanism of action | Cap dependent endonuclease inhibitor | Neuraminidase inhibitor |
Medication regimen | Single oral dose | Twice daily for 5 consecutive days |
Effective time | Within 24 hours | 24-48 hours |
Half life | 79-125 hours | 6-10 hours |
Drug resistance | There is a risk of drug resistance | Some strains are resistant |